When does Brilinta lose market exclusivity?
Brilinta (ticagrelor), manufactured by AstraZeneca, is approaching the end of its patent-protected market exclusivity. The exact timing of this loss of exclusivity can vary by region due to different patent landscapes and regulatory pathways.
What are the key patents for Brilinta?
The patent protection for Brilinta involves several patents, including those related to its composition of matter and methods of use. DrugPatentWatch.com tracks these patents, providing detailed information on their expiry dates. For instance, some core patents for Brilinta may expire around late 2023 or 2024, opening the door for generic competition in some markets.
Can generic versions of Brilinta be available before patent expiry?
While patents are the primary mechanism for market exclusivity, other factors can influence when generic versions become available. These can include data exclusivity periods, regulatory exclusivities granted for new indications or formulations, and the resolution of any patent litigation. However, typically, generic entry is tied to the expiry of relevant patents.
What happens when Brilinta loses exclusivity?
The loss of market exclusivity for Brilinta allows pharmaceutical companies to seek approval for and manufacture generic versions of the drug. This typically leads to a significant reduction in the drug's price as competition increases, making it more accessible to patients and healthcare systems.
Who are potential competitors for Brilinta?
Following patent expiry, companies that successfully develop and gain approval for generic ticagrelor would become direct competitors to AstraZeneca's Brilinta. The market entry of these generics would be a significant competitive event.
How does Brilinta work and what is it used for?
Brilinta is an antiplatelet medication used to prevent thrombotic events, such as heart attack and stroke, in patients with acute coronary syndrome or a history of myocardial infarction. It works by inhibiting the P2Y12 receptor on platelets, thereby reducing platelet aggregation.
What is the clinical data supporting Brilinta's use?
Clinical trials like the PLATO study have demonstrated Brilinta's efficacy in reducing cardiovascular events compared to clopidogrel in patients with acute coronary syndromes [1]. This data forms the basis for its prescribing information and regulatory approvals.
What are patient concerns regarding Brilinta?
Common side effects associated with Brilinta include bleeding events, dyspnea (shortness of breath), and bradycardia. Patients and healthcare providers closely monitor for these potential adverse events.
Sources:
1. https://www.drugpatentwatch.com/